Market Overview:
The global metabolic disorder therapeutics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of metabolic disorders, rising awareness about available treatments, and technological advancements in the field of metabolic disorder therapeutics. The diabetes segment is expected to account for the largest share of the global market in 2018 owing to its high prevalence across all regions. The obesity segment is projected to grow at the highest CAGR during the forecast period due to increasing incidence rates globally. On basis if application ,the oral therapeutic drugs are estimated dominate th emarket with more than 50% share by 2030 end .
Product Definition:
Metabolic disorder therapeutics is a branch of pharmacology that deals with the treatment of metabolic disorders. Metabolic disorders are conditions that affect how the body uses food to produce energy. Metabolic disorder therapeutics is important because it helps to treat conditions that can lead to serious health problems, such as obesity, heart disease, and diabetes.
Lysosomal Storage Diseases:
Lysosomal storage diseases (LSD) are a group of rare metabolic disorders caused by genetic mutations resulting in the accumulation of unprocessed lysosomes within various body tissues and organs. The most common symptom exhibited by patients with LSD is usually a life-threatening one which is often referred to as Fabry disease or lysosomal storage disorder. Other symptoms include early death in middle-aged individuals, infantile mortality, and abnormal skin lesions.
Diabetes:
Diabetes is a metabolic disorder wherein the inability of the pancreas to produce insulin causes decreased glucose levels in the body. Glucose is an essential element for all types of cells in the human body and its deficiency leads to several health risks. The global diabetes market was valued at USD 12 billion in 2014 and it is expected to grow at a CAGR of XX% over the forecast period.
Application Insights:
Metabolic disorders are classified into five application segments including oral, parenteral, others and unmet needs. Among these other applications include surgical resection and transplantation therapies. Parenteral includes insulin therapy for the treatment of diabetes mellitus. The others segment includes nutritional support and enteral/parenteral nutrition in the case of patients who cannot tolerate or do not respond to a gluten-free diet due to celiac disease or dietary refusal due to religious reasons among other factors such as age, weight & height etc. Oral metabolic disorder therapeutics include enzyme replacement therapy (ERT) for the treatment of glycosylation disorders such as iduronate-2-sulphatase deficiency (IDUS), stachydrophylline sulfonium complex deficiency (SSSD), galactosidosis type Ia (GAL1A) among others which have no cure with available drugs currently available in the market place thus driving growth over forecast period.
Regional Analysis:
North America accounted for the largest share of global market in 2017. The presence of a large number of key players, favorable reimbursement scenario, and increasing prevalence of obesity are some factors contributing to its growth. In addition, growing awareness about metabolic disorders among people is also expected to drive the regional market over the forecast period.
Asia Pacific is estimated to be one of the fastest-growing regions during the forecast period owing to rising healthcare expenditure by governments and private sectors in countries such as China and India. Moreover, increasing investment by companies for manufacturing generic drugs will boost this regional market further. Growing awareness about metabolic disorders among people will also support region’s growth over next six years due to rise in diabetes cases especially type 2 diabetes which has become epidemic in developing countries like India and China (1).
Growth Factors:
- Increasing prevalence of metabolic disorders such as obesity, type 2 diabetes, and heart diseases.
- Growing awareness about the benefits of early diagnosis and treatment of metabolic disorders among patients and healthcare professionals.
- Rising demand for novel therapeutics for the treatment of metabolic disorders.
- increasing research funding for the development of new drugs for the treatment of metabolic disorders by government and private organizations worldwide .
Scope Of The Report
Report Attributes
Report Details
Report Title
Metabolic Disorder Therapeutics Market Research Report
By Type
Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia
By Application
Oral, Parenteral, Others
By Companies
Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck KgaA, Amgen, Inc., AstraZeneca PLC, Actelion Pharmaceuticals Ltd., Shire PLC, AbbVie, Inc., Biocon Ltd., BioMarin Pharmaceutical, Inc., Bristol-Myers Squibb Company, Cipla, Inc., CymaBay Therapeutics, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
166
Number of Tables & Figures
117
Customization Available
Yes, the report can be customized as per your need.
Global Metabolic Disorder Therapeutics Market Report Segments:
The global Metabolic Disorder Therapeutics market is segmented on the basis of:
Types
Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oral, Parenteral, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk A/S
- Sanofi S.A.
- Boehringer Ingelheim GmbH
- Eli Lilly and Company
- Merck KgaA
- Amgen, Inc.
- AstraZeneca PLC
- Actelion Pharmaceuticals Ltd.
- Shire PLC
- AbbVie, Inc.
- Biocon Ltd.
- BioMarin Pharmaceutical, Inc.
- Bristol-Myers Squibb Company
- Cipla, Inc.
- CymaBay Therapeutics, Inc.
Highlights of The Metabolic Disorder Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Lysosomal Storage Diseases
- Diabetes
- Obesity
- Inherited Metabolic Disorders
- Hypercholesterolemia
- By Application:
- Oral
- Parenteral
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metabolic Disorder Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metabolic disorder therapeutics is a field of medicine that focuses on the treatment of metabolic disorders. These disorders can be caused by a number of factors, including genetics and lifestyle choices. Treatment typically involves medications and/or surgery.
Some of the major companies in the metabolic disorder therapeutics market are Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck KgaA, Amgen, Inc., AstraZeneca PLC, Actelion Pharmaceuticals Ltd., Shire PLC, AbbVie, Inc., Biocon Ltd., BioMarin Pharmaceutical, Inc., Bristol-Myers Squibb Company, Cipla, Inc., CymaBay Therapeutics, Inc..
The metabolic disorder therapeutics market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Metabolic Disorder Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Metabolic Disorder Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Metabolic Disorder Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Metabolic Disorder Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Metabolic Disorder Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Metabolic Disorder Therapeutics Market Size and Y-o-Y Growth
4.5.2 Metabolic Disorder Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Metabolic Disorder Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Metabolic Disorder Therapeutics Market Size Forecast by Type
5.2.1 Lysosomal Storage Diseases
5.2.2 Diabetes
5.2.3 Obesity
5.2.4 Inherited Metabolic Disorders
5.2.5 Hypercholesterolemia
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Metabolic Disorder Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Metabolic Disorder Therapeutics Market Size Forecast by Applications
6.2.1 Oral
6.2.2 Parenteral
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Metabolic Disorder Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Metabolic Disorder Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Metabolic Disorder Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Metabolic Disorder Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Metabolic Disorder Therapeutics Market Size Forecast by Type
9.6.1 Lysosomal Storage Diseases
9.6.2 Diabetes
9.6.3 Obesity
9.6.4 Inherited Metabolic Disorders
9.6.5 Hypercholesterolemia
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Metabolic Disorder Therapeutics Market Size Forecast by Applications
9.10.1 Oral
9.10.2 Parenteral
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Metabolic Disorder Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Metabolic Disorder Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Metabolic Disorder Therapeutics Market Size Forecast by Type
10.6.1 Lysosomal Storage Diseases
10.6.2 Diabetes
10.6.3 Obesity
10.6.4 Inherited Metabolic Disorders
10.6.5 Hypercholesterolemia
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Metabolic Disorder Therapeutics Market Size Forecast by Applications
10.10.1 Oral
10.10.2 Parenteral
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Metabolic Disorder Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Metabolic Disorder Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Metabolic Disorder Therapeutics Market Size Forecast by Type
11.6.1 Lysosomal Storage Diseases
11.6.2 Diabetes
11.6.3 Obesity
11.6.4 Inherited Metabolic Disorders
11.6.5 Hypercholesterolemia
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Metabolic Disorder Therapeutics Market Size Forecast by Applications
11.10.1 Oral
11.10.2 Parenteral
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Metabolic Disorder Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Metabolic Disorder Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Metabolic Disorder Therapeutics Market Size Forecast by Type
12.6.1 Lysosomal Storage Diseases
12.6.2 Diabetes
12.6.3 Obesity
12.6.4 Inherited Metabolic Disorders
12.6.5 Hypercholesterolemia
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Metabolic Disorder Therapeutics Market Size Forecast by Applications
12.10.1 Oral
12.10.2 Parenteral
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Metabolic Disorder Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Metabolic Disorder Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Metabolic Disorder Therapeutics Market Size Forecast by Type
13.6.1 Lysosomal Storage Diseases
13.6.2 Diabetes
13.6.3 Obesity
13.6.4 Inherited Metabolic Disorders
13.6.5 Hypercholesterolemia
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Metabolic Disorder Therapeutics Market Size Forecast by Applications
13.10.1 Oral
13.10.2 Parenteral
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Metabolic Disorder Therapeutics Market: Competitive Dashboard
14.2 Global Metabolic Disorder Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novo Nordisk A/S
14.3.2 Sanofi S.A.
14.3.3 Boehringer Ingelheim GmbH
14.3.4 Eli Lilly and Company
14.3.5 Merck KgaA
14.3.6 Amgen, Inc.
14.3.7 AstraZeneca PLC
14.3.8 Actelion Pharmaceuticals Ltd.
14.3.9 Shire PLC
14.3.10 AbbVie, Inc.
14.3.11 Biocon Ltd.
14.3.12 BioMarin Pharmaceutical, Inc.
14.3.13 Bristol-Myers Squibb Company
14.3.14 Cipla, Inc.
14.3.15 CymaBay Therapeutics, Inc.
